Macomics has a portfolio of modality-agnostic therapeutic candidates, including antibody and small molecule programs, progressing towards the clinic.

Macomics will continue to expand its portfolio of validated targets in diseases where macrophages play a central role in aetiology, response to therapy, and patient outcomes.